All In Biotech

Drug Trial Radar · NCT00355368

Succinylcholine Versus Rocuronium for Emergency Intubation in Intensive Care

Phase 4 Study of Succinylcholine Versus Rocuronium as Neuromuscular Blocking Agent for Emergency Intubation in Intensive Care

Last checked: Nov 20, 2026Latest source record: Dec 15, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

420

Actual

Start

Aug 2006

Primary completion

Aug 2006

Study completion Jul 2010

Sponsor

Lead sponsor
University Hospital, Basel, SwitzerlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Emergency intubation of patients in intensive care is a high-risk endeavour. For many decades, succinylcholine has been the neuromuscular blocking agent of choice. However, succinylcholine may have life-threatening side effects and is contraindicated in a variety of diseases relevant in intensive care. The nondepolarizing agent rocuronium has been propagated as alternative for succinylcholine. Though a recent meta-analysis found no difference in intubating conditions between succinylcholine and rocuronium in elective cases, there are no data in emergent cases in intensive care. The aim of the present study is to compare succinylcholine and rocuronium with regard to 1) quality of intubating conditions, 2) length of the intubating sequence, 3) failed intubating attempts, 4) hemodynamic sequelae of intubation, and 5) desaturations.

Conditions

  • Intubation

Interventions

  • SuccinylcholineDrug

    1mg/kg iv

  • RocuroniumDrug

    0.6mg/kg iv

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Exhibiting Desaturation >5%Time frame: at any time between the start of the intubation sequence and 2min after the completion of intubation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Medical Intensive Care; University of Basel

    Basel, Canton of Basel-City, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.